Pharming Group to participate in February investor conference
February 10, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
WISeKey’s WISeID Empowers Users with Digital Identity Control in a Geopolitically Uncertain World
February 10, 2025 01:00 ET
|
Wisekey International Holding Ltd.
WISeKey’s WISeID Empowers Users with Digital Identity Control in a Geopolitically Uncertain World Geneva, Switzerland, February 10, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN,...
Unlocking AI’s Full Potential: EXL's "AI in Action" Event Will Showcase Real-World Strategies to Scale AI for Business Leaders in ANZ
February 09, 2025 17:30 ET
|
Exlservice Holdings, Inc.
EXL's "AI in Action" Event Will Showcase Real-World Strategies to Scale AI for Business Leaders in ANZ
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
February 08, 2025 17:40 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial...
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
February 08, 2025 15:55 ET
|
Regeneron Pharmaceuticals, Inc.
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%,...
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
February 08, 2025 14:30 ET
|
4D Molecular Therapeutics, Inc.
3E10 vg/eye achieved an 83% reduction in injection burden vs. projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection, and 57% were injection-free through 52 weeksIn the...
Intchains Group Limited’s Goldshell launches its first ever ALEO miner today: AE BOX promises users ultimate crypto mining privacy and security
February 08, 2025 00:34 ET
|
Intchains Group Limited
SINGAPORE, Feb. 08, 2025 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG), an innovative provider of integrated solutions consisting of efficient mining products for altcoins, is excited to...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
February 07, 2025 18:35 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Matthews International Issues Statement Following ISS Report
February 07, 2025 18:30 ET
|
Matthews International Corporation
PITTSBURGH, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) (“Matthews” or the “Company”) issued the following statement regarding a February 6, 2025 report...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
February 07, 2025 16:58 ET
|
Pliant Therapeutics, Inc.
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO,...